Skip to main content
SpringerLink
Log in

Glycated albumin (GA) and the GA/HbA1c ratio are higher in diabetic patients positive for insulin antibodies with high binding capacity and low affinity

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Patients with diabetes mellitus having insulin antibodies (InsAb) with properties of high binding capacity and low affinity, which are observed in insulin autoimmune syndrome (IAS), are known to have greater plasma glucose fluctuations. Glycated albumin (GA) and the GA/HbA1c ratio have been demonstrated to reflect plasma glucose fluctuations. Hence, we hypothesized that GA or the GA/HbA1c ratio in diabetic patients having InsAb with properties of high binding capacity and low affinity may be higher than those in InsAb-negative diabetic patients, and we verified this hypothesis. Subjects were 12 diabetic patients who had InsAb noted while being treated with insulin and were subjected to Scatchard analysis and whose InsAb had properties similar to those of patients with IAS (affinity constant K1 < 0.24 × 1/10–8 M, number of binding sites R1 ≥ 11.5 × 10–8 M) [four cases of type 1 diabetes (T1D) and eight cases of type 2 diabetes (T2D)]. The control group consisted of T1D and T2D cases matched to the T1D and T2D cases, respectively, according to sex, age, BMI, and HbA1c. GA and the GA/HbA1c ratio were compared between both groups. GA and the GA/HbA1c ratio in InsAb-positive patients was significantly higher than that in the control group for both T1D and T2D patients. Diabetic patients having InsAb with properties of high binding capacity and low affinity had higher GA and the GA/HbA1c ratio than those of InsAb-negative patients. Greater plasma glucose fluctuations were suggested in InsAb-positive diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev. 2007;28:625–52.

    Article  CAS  Google Scholar 

  2. Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care. 1979;2:283–95.

    Article  CAS  Google Scholar 

  3. Eguchi Y. Scatchard analysis of insulin autoantibodies in the insulin autoimmune syndrome. Tokyo Joshi Ikadaigaku Zasshi. 1989;59:1296–305.

    Google Scholar 

  4. Baxter RC, Yue DK, Turtle JR. Equilibrium binding studies of insulin antibodies in diabetic subjects. Clin Chem. 1976;22:1089–94.

    Article  CAS  Google Scholar 

  5. Hu X, Chen F. Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients. Endocr Connect. 2018;7:R47-55.

    Article  CAS  Google Scholar 

  6. Hirota Y, Ogawa W, Murawaki A, Nishiumi T, Komada H, Miyake K, Sakaguchi K, Kasuga M. Deterioration of glycaemic control associated with anti-insulin antibodies likely induced by health supplements. Diabet Med. 2009;26:948–51.

    Article  CAS  Google Scholar 

  7. Yoshida M, Murakami M, Ogawa K, Asai M, Miyata M, Maeda H, Oiso Y. Repeated hypoglycemia caused by the overproduction of anti-insulin antibodies and isolated ACTH deficiency in a type 2 diabetic patient receiving insulin therapy. Diabetes Care. 2013;36: e22.

    Article  Google Scholar 

  8. Uchigata Y, Kuwata S, Tsushima T, Tokunaga K, Miyamoto M, Tsutchikawa K, Hirata Y, Juji T, Omori Y. Patients with Graves’ disease who developed in- sulin sutoimmune syndrome (Hirata’ disease), possess HLA-Bw62/Cw4/DR4 carrying CRB1*0406. J Clin Endocrinol Metab. 1993;77:249–54.

    CAS  PubMed  Google Scholar 

  9. Ishida Y, Ohara T, Okuno Y, Ito T, Hirota Y, Furukawa K, Sakaguchi K, Ogawa W, Kasuga M. Alpha-lipoic acid and insulin autoimmune syndrome. Diabetes Care. 2007;30:2240–1.

    Article  CAS  Google Scholar 

  10. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18:440–7.

    Article  CAS  Google Scholar 

  11. Suwa T, Ohta A, Matsui T, Koganei R, Kato H, Kawata T, Sada Y, Ishii S, Kondo A, Murakami K, Katabami T, Tanaka Y. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J. 2010;57:135–40.

    Article  CAS  Google Scholar 

  12. Tsutsumi C, Imagawa A, Onishi M, Sano H, Nakagawa S, Murase-Mishiba Y, Terasaki J, Hanafusa T. Glycated albumin as a useful clinical biomarker for glycemic variability in type 1 diabetes assessed by continuous glucose monitoring. Diabetol Int. 2013;4:156–9.

    Article  Google Scholar 

  13. Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care. 2010;33:270–2.

    Article  CAS  Google Scholar 

  14. Ogawa A, Hayashi A, Kishihara E, Yoshino S, Takeuchi A, Shichiri M. New indices for predicting glycaemic variability. PLoS ONE. 2012;7: e46517.

    Article  CAS  Google Scholar 

  15. Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T, Umayahara Y, Kosugi K, Kaneto H, Yamasaki Y, Hori M. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008;55:503–7.

    Article  CAS  Google Scholar 

  16. Hirata Y. Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet. 1983;2:1037–8.

    Article  CAS  Google Scholar 

  17. Koga M, Inada S, Taniguchi J, Nakatani Y, Yoshino H, Yoshino G, Okauchi Y, Mineo I. High glycated albumin (GA) levels and the GA/HbA1c ratio in patients with insulin autoimmune syndrome. Diabetol Int. 2016;8:199–204.

    Article  Google Scholar 

  18. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.

    Article  Google Scholar 

  19. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta. 2002;324:61–71.

    Article  CAS  Google Scholar 

  20. Greenfield JR, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, O’Rahilly S. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet Med. 2009;26:79–82.

    Article  CAS  Google Scholar 

  21. Su CT, Lin YC. Hyper insulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog. Endocrinol Diabetes Metab Case Rep. 2016;2016:16–0079.

    PubMed  PubMed Central  Google Scholar 

  22. Matsuyoshi A, Shimoda S, Tsuruzoe K, Taketa K, Chirioka T, Sakamoto F, Sakakida M, Miyamura N, Araki E. A case of slowly progressive type 1 diabetes with unstable glycemic control caused by unusual insulin antibody and successfully treated with steroid therapy. Diabetes Res Clin Pract. 2006;72:238–43.

    Article  CAS  Google Scholar 

  23. Honda M, Kawashima Y, Kawamura H, Fujikawa H, Kikuchi K, Ohashi H, Mori Y, Miyakawa H, Ishibashi M. Acute liver dysfunction complicated with uncontrollable glycemia due to insulin antibody: successful treatment with glucocorticoid and lispro insulin. Intern Med. 2006;45:1225–9.

    Article  Google Scholar 

  24. Taya N, Kato K, Oida T, Mitsui E, Taki H. A case of diabetes mellitus with fasting hyperglycemia due to changes in the characteristics of insulin antibodies after the administration of an insulin analogue (Glargine). J Japan Diab Soc. 2019;62:170–7.

    Google Scholar 

  25. Segal T, Webb E, Viner R, Pusey C, Wild G, Allgrove J. Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. Pediatr Diabetes. 2008;9:250–4.

    Article  CAS  Google Scholar 

  26. Murakami A, Nomiyama T, Takahashi H, Kita S, Yamao Y, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D. The effect of GLP-1 receptor agonist dulaglutide on aggravated glycemic control due to anti-insulin antibody in a patient with type 2 diabetes mellitus: a case report. J Japan Diab Soc. 2020;63:139–45.

    Google Scholar 

  27. Hayashi A, Takano K, Kawai S, Shichiri M. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies. Endocr J. 2016;63:187–91.

    Article  CAS  Google Scholar 

  28. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro A case report. Diabetes Care. 1997;20:71–3.

    Article  CAS  Google Scholar 

  29. Itoh A, Saisho Y, Mitsuishi M, Oikawa Y, Kawai T, Tanaka M, Shimada A, Itoh H. Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody–a case report. Diabetes Res Clin Pract. 2011;94:e53–4.

    Article  Google Scholar 

  30. Vazeou A. Continuous blood glucose monitoring in diabetes treatment. Diabetes Res Clin Pract. 2011;93:S125–30.

    Article  Google Scholar 

  31. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–94.

    Article  CAS  Google Scholar 

  32. Mukai N, Ohara T, Hata J, Hirakawa Y, Yoshida D, Kishimoto H, Koga M, Nakamura U, Kitazono T, Kiyohara Y, Ninomiya T. Alternative measures of hyperglycemia and risk of alzheimer’s disease in the community: The Hisayama study. J Clin Endocrinol Metab. 2017;102:3002–10.

    Article  Google Scholar 

Download references

Acknowledgements

We conducted this research and observed the Declaration of Helsinki and current ethical codes, and the research was approved by the ethics committee of Kobe University Graduate School of Medicine [approval number of Ethics Committee 180172] at November 26, 2018.

Author information

Authors and Affiliations

  1. Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Kobe, 650-0017, Japan

    Takehito Takeuchi, Yushi Hirota, Yasushi Nakagawa, Atsuko Matsuoka, Tetsushi Hamaguchi, Yuko Okada, Kazuhiko Sakaguchi & Wataru Ogawa

  2. Department of Internal Medicine, Hakuhokai Central Hospital, Hyogo, Japan

    Masafumi Koga

Authors
  1. Takehito Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yushi Hirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsuko Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsushi Hamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuko Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiko Sakaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wataru Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masafumi Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yushi Hirota.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest associated with this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takeuchi, T., Hirota, Y., Nakagawa, Y. et al. Glycated albumin (GA) and the GA/HbA1c ratio are higher in diabetic patients positive for insulin antibodies with high binding capacity and low affinity. Diabetol Int 13, 226–231 (2022). https://doi.org/10.1007/s13340-021-00528-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-021-00528-z

Keywords

Search

Navigation